Comparison of Heparin and Clexane in Thrombosis Prevention after Craniotomy

Efficacy Comparison of Unfractionated Heparin and Low Molecular Weight Heparin(LMWH) in Deep Vein Thrombosis Prophylaxis for Brain Tumor craniotomy

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2012102711274N1

Enrollment

154

Registered

2013-06-08

Start date

2008-07-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deep Vein Thrombosis. Phlebitis and Thrombophlebitis of other Deep Vessels of Lower Extremities

Interventions

Intervention 1: intervention group: patients received subcutaneous clexane (40mg/d) 48 hours after craniotomy (Noxparin 40 made by Alborz Darou). treatment continues until patients become mobile or ma

Treatment - Drugs

intervention group: patients received subcutaneous clexane (40mg/d) 48 hours after craniotomy (Noxparin 40 made by Alborz Darou). treatment continues until patients become mobile or maximum one week.

control group: patients received subcutaneous unfractionated heparin (5000 Iu/12h) Heparodic 5000 made by Caspian Tamin Pharmaceutical Co. 48 hours after craniotomy, treatment continues until patients

Eligibility

Sex/Gender

All

Age

36 Years to 62 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : Patients candidate for elective craniotomy due to brain tumor were enrolled in this randomized, double – blinded, controlled clinical trial from 2009 to 2010 in Isfahan IRAN. exclusion criteria : Patients with bleeding into the primary lesion; history of thrombotic events in the post 6 moths; or recent anticoagulation use were excluded. Patients that due to Paresis or plegia weren't ambulated even though treatment continued, excluded from our study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Deep Vein Thrombosis. Timepoint: Before intervention , After intervention daily (from 48 h after operation) until 7 days. Method of measurement: 1)Questionnaire, 2)Physical Examination 3) if any doubt remained Doppler Sonography was used.	—

Secondary

Measure	Time frame
Blood Hypertention. Timepoint: Daily Physical Exams. Method of measurement: Daily physical exam.;Smoking history. Timepoint: Before intervention. Method of measurement: Questionnaire.;Diabetes Mellitus. Timepoint: Daily Physical Exams. Method of measurement: Lab Data.;Trombocytopenia. Timepoint: Daily. Method of measurement: Lab Data.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNourallah Eshraghi

Isfahan Medical University

n_eshraghi@resident.mui.ac.ir neshraghi@yahoo.com+98 31 1668 5555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026